News

FDA approves NRx's preservative-free ketamine injection, made in the US

What's the deal? The US Food and Drug Administration (FDA) has approved NRx Pharmaceuticals' Abbreviated New Drug Application (ANDA) for Preservative-Free Ketamine, clearing the injectable anaesthetic for the US market ahead of the FDA's 10 November 2026 goal date. The approval was announced on 30 October 2026.

Why it matters: Ketamine, first formulated in 1970, is one of the last sterile drugs still containing benzethonium chloride (BZT), an antimicrobial preservative the FDA does not recognise as safe. BZT is toxic to epithelial cells — the cells lining organs — and is banned from new drugs and hand sanitisers. NRx's version removes it, and is manufactured in the United States with Nephron Pharmaceuticals in West Columbia, South Carolina, using modern high-volume blow-fill-seal technology — a move the company says helps end the shortage of traditional glass-bottled ketamine and brings sterile injectable manufacturing back to the US. NRx develops medicines for depression, PTSD and suicidality; the approval is a step toward commercialising its first product.

Read more: GlobeNewswire, 30 October 2026

More top stories